In short
This article discusses the ongoing clinical trials of NX-13, a novel drug being tested for the treatment of moderate to severe ulcerative colitis. NX-13 contains the active substance 1,3,5-Tris(6-Methylpyridin-2-Yloxy)Benzene and is being evaluated for its safety, tolerability, and effectiveness in managing this chronic inflammatory bowel disease.
At a glance
- Drug Name
- NX-13 (1,3,5-Tris(6-Methylpyridin-2-Yloxy)Benzene)
- Condition Treated
- Moderate to Severe Ulcerative Colitis
- Trial Phase
- Phase 2
- Trial Design
- Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter
- Duration
- 12-week induction period + 40-week long-term extension
- Primary Endpoint
- Change from baseline in Modified Mayo Score (MMS) at Week 12
- Key Secondary Endpoints
- Safety, tolerability, clinical remission, clinical response, endoscopic response, endoscopic remission, symptomatic remission
- Administration
- Oral tablets, maximum daily dose 750 mg
- Eligibility
- Adults 18-75 years with moderate to severe ulcerative colitis, inadequate response to previous therapies
What is NX-13?
NX-13 is a new medication being studied for the treatment of moderate to severe ulcerative colitis. Ulcerative colitis is a type of inflammatory bowel disease that causes inflammation and sores (ulcers) in the lining of the large intestine (colon) and rectum. The active ingredient in NX-13 is a chemical compound called 1,3,5-TRIS(6-METHYLPYRIDIN-2-YLOXY)BENZENE.
How NX-13 Works
While the exact mechanism of action is not fully described in the trial information, NX-13 is being developed as an oral medication for ulcerative colitis. It is designed to target the underlying inflammation in the colon that causes the symptoms of ulcerative colitis.
Clinical Trial Details
NX-13 is currently being studied in a Phase 2 clinical trial. This trial is designed to evaluate how well NX-13 works and how safe it is for people with moderate to severe ulcerative colitis. Here are some key details about the trial:
- It is a randomized, double-blind, placebo-controlled study. This means that participants are randomly assigned to receive either NX-13 or a placebo, and neither the participants nor the researchers know who is receiving which treatment.
- The trial consists of a 12-week induction period followed by a 40-week long-term extension period.
- The main goal is to assess the clinical activity of oral NX-13 compared to placebo.
Who Can Participate in the NX-13 Trial?
The trial is looking for participants who meet specific criteria, including:
- Adults aged 18 to 75 years
- Diagnosed with ulcerative colitis for at least 3 months before screening
- Have moderate to severe disease activity
- Have not responded well to, lost response to, or cannot tolerate at least one conventional or biologic therapy for ulcerative colitis
There are also several exclusion criteria, such as having certain other medical conditions or taking specific medications, which might prevent someone from participating in the trial.
Potential Benefits of NX-13
The trial aims to measure several potential benefits of NX-13, including:
- Clinical remission: This means that the symptoms of ulcerative colitis have significantly improved or disappeared.
- Clinical response: This refers to a noticeable improvement in symptoms.
- Endoscopic response and remission: These measure improvements in the appearance of the colon lining when viewed through an endoscope.
- Symptomatic remission: This focuses on the improvement of specific symptoms like rectal bleeding and stool frequency.
Safety Considerations
As with any new medication, safety is a crucial aspect of the NX-13 trial. The researchers will be closely monitoring:
- The proportion of participants who experience side effects (called treatment-emergent adverse events or TEAEs)
- Any serious adverse events that occur during the trial
- Changes in laboratory test results, vital signs, and ECGs (heart tests) over time
It's important to note that while NX-13 shows promise, it is still an experimental medication. More research is needed to fully understand its effectiveness and safety profile for treating ulcerative colitis.